
Young Joon Byun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6916926/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer. Prostate International, 2022, 10, 1-6.	2.3	5
2	Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone. Investigative and Clinical Urology, 2022, 63, 238.	2.0	3
3	Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	2
4	A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 237.e21-237.e29.	1.6	12
5	Collagen typeÂVlâ€Î±1 and 2 repress the proliferation, migration and invasion of bladder cancer cells. International Journal of Oncology, 2021, 59, .	3.3	21
6	Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer. Investigative and Clinical Urology, 2021, 62, 340.	2.0	14
7	Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression. International Journal of Molecular Sciences, 2021, 22, 12756.	4.1	7
8	A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters, 2020, 19, 476-486.	1.8	9
9	A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone. Investigative and Clinical Urology, 2020, 61, 411.	2.0	7
10	Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, e704-e711.	1.9	12
11	ZNF492 and GPR149 methylation patterns as prognostic markers for clear cell renal cell carcinoma: Arrayâ€ʿbased DNA methylation profiling. Oncology Reports, 2019, 42, 453-460.	2.6	6
12	Urinary cellâ€free microRNA biomarker could discriminate bladder cancer from benign hematuria. International Journal of Cancer, 2019, 144, 380-388.	5.1	30
13	Diagnostic value of combined IQCAP3/BMP4 and IQCAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 86-96.	1.6	11
14	Methylation Signature for Prediction of Progression Free Survival in Surgically Treated Clear Cell Renal Cell Carcinoma. Journal of Korean Medical Science, 2019, 34, e144.	2.5	17
15	Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 274-280.	1.9	8
16	<i>CDC6</i> mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer. Journal of Korean Medical Science, 2018, 33, e303.	2.5	19
17	Identification of differentially expressed miRNAs and miRNA-targeted genes in bladder cancer. Oncotarget, 2018, 9, 27656-27666.	1.8	20
18	Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness. Clinical Genitourinary Cancer, 2017, 15, 450-454.	1.9	14